Pulmonary Aspergillosis in Critically Ill COVID-19 Patients Admitted to the Intensive Care Unit: A Retrospective Cohort Study
- PMID: 36983483
- PMCID: PMC10054145
- DOI: 10.3390/jof9030315
Pulmonary Aspergillosis in Critically Ill COVID-19 Patients Admitted to the Intensive Care Unit: A Retrospective Cohort Study
Abstract
COVID-19-associated pulmonary aspergillosis (CAPA) is a life-threatening fungal infection that mainly affects critically ill patients. The aim of this study was to assess the incidence and clinical outcomes of putative CAPA in critically ill COVID-19 patients. This retrospective observational cohort study included 181 cases from 5 ICUs at Vienna General Hospital between January 2020 and April 2022. Patients were diagnosed with putative CAPA according to the AspICU classification, which included a positive Aspergillus culture in a bronchoalveolar lavage sample, compatible signs and symptoms, and abnormal medical imaging. The primary outcome was adjusted 60-day all-cause mortality from ICU admission in patients with vs. without putative CAPA. Secondary outcomes included time from ICU admission to CAPA diagnosis and pathogen prevalence and distribution. Putative CAPA was identified in 35 (19.3%) of 181 COVID-19 patients. The mean time to diagnosis was 9 days. Death at 60 days occurred in 18 of 35 (51.4%) patients with CAPA and in 43 of 146 (29.5%) patients without CAPA (adjusted HR (95%CI) = 2.15 (1.20-3.86, p = 0.002). The most frequently isolated Aspergillus species was Aspergillus fumigatus. The prevalence of putative pulmonary aspergillosis in critically ill COVID-19 patients was high and was associated with significantly higher mortality.
Keywords: CAPA; ICU; IPA; SARS-CoV-2; aspergillus; co-infection; fungal.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
A screening study for COVID-19-associated pulmonary aspergillosis in critically ill patients during the third wave of the pandemic.Mycoses. 2022 Jul;65(7):724-732. doi: 10.1111/myc.13466. Epub 2022 May 25. Mycoses. 2022. PMID: 35531631 Free PMC article.
-
Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study.Lancet Respir Med. 2022 Dec;10(12):1147-1159. doi: 10.1016/S2213-2600(22)00259-4. Epub 2022 Aug 24. Lancet Respir Med. 2022. PMID: 36029799 Free PMC article.
-
A Regional Observational Study on COVID-19-Associated Pulmonary Aspergillosis (CAPA) within Intensive Care Unit: Trying to Break the Mold.J Fungi (Basel). 2022 Nov 30;8(12):1264. doi: 10.3390/jof8121264. J Fungi (Basel). 2022. PMID: 36547597 Free PMC article.
-
COVID-19-Associated Pulmonary Aspergillosis (CAPA).J Intensive Med. 2021 Aug 7;1(2):71-80. doi: 10.1016/j.jointm.2021.07.001. eCollection 2021 Oct. J Intensive Med. 2021. PMID: 36785564 Free PMC article. Review.
-
Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity.Mycoses. 2021 Feb;64(2):132-143. doi: 10.1111/myc.13213. Epub 2020 Nov 29. Mycoses. 2021. PMID: 33210776 Free PMC article. Review.
Cited by
-
Epidemiology and Azole Resistance of Clinical Isolates of Aspergillus fumigatus from a Large Tertiary Hospital in Ningxia, China.Infect Drug Resist. 2024 Feb 2;17:427-439. doi: 10.2147/IDR.S440363. eCollection 2024. Infect Drug Resist. 2024. PMID: 38328338 Free PMC article.
-
Pharmacokinetics of isavuconazole at different target sites in healthy volunteers after single and multiple intravenous infusions.J Antimicrob Chemother. 2024 May 2;79(5):1169-1175. doi: 10.1093/jac/dkae088. J Antimicrob Chemother. 2024. PMID: 38546795 Free PMC article.
-
Outcomes of Patients with COVID-19 and Fungal Coinfections: A Systematic Review and Meta-Analysis Study.Iran J Pathol. 2024 Spring;19(2):136-147. doi: 10.30699/IJP.2024.2010087.3160. Epub 2024 Feb 15. Iran J Pathol. 2024. PMID: 39118795 Free PMC article. Review.
-
Clinical courses and outcomes of COVID-19 associated pulmonary aspergillosis in 168 patients with the SARS-CoV-2 omicron variant.BMC Infect Dis. 2024 Jan 23;24(1):117. doi: 10.1186/s12879-023-08971-w. BMC Infect Dis. 2024. PMID: 38263011 Free PMC article.
References
-
- Gabelloni M., Faggioni L., Cioni D., Mendola V., Falaschi Z., Coppola S., Corradi F., Isirdi A., Brandi N., Coppola F., et al. Extracorporeal Membrane Oxygenation (ECMO) in COVID-19 Patients: A Pocket Guide for Radiologists. Radiol. Med. 2022;127:369–382. doi: 10.1007/s11547-022-01473-w. - DOI - PMC - PubMed
-
- Bartoletti M., Pascale R., Cricca M., Rinaldi M., Maccaro A., Bussini L., Fornaro G., Tonetti T., Pizzilli G., Francalanci E., et al. Epidemiology of Invasive Pulmonary Aspergillosis among Intubated Patients with COVID-19: A Prospective Study. Clin. Infect. Dis. 2021;73:E3606–E3614. doi: 10.1093/cid/ciaa1065. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous